Sutro Biopharma Raises $110M in Public Offering, Extending Cash Runway to Q2 2028

summarizeSummary

Sutro Biopharma completed a public offering of 7.87 million common shares at $13.98 each, raising approximately $102.7 million in net proceeds to fund its clinical pipeline and operations, extending its cash runway into Q2 2028.

check_boxKey Events

• Public Offering Details

  The company offered 7,868,383 shares of common stock at an offering price of $13.98 per share, totaling approximately $110 million before underwriting discounts and commissions.

• Net Proceeds and Use

  Sutro Biopharma expects to receive net proceeds of approximately $102.7 million, which will be used for general corporate purposes, including funding research, clinical development, and manufacturing of product candidates.

• Extended Cash Runway

  The capital raise, combined with existing cash, is estimated to provide sufficient funds to support operating expenses and capital expenditures into the second quarter of 2028.

• Significant Dilution

  The offering is highly dilutive, increasing the number of outstanding common shares by approximately 91.88% based on shares outstanding as of September 30, 2025, resulting in immediate and substantial dilution for new investors.

auto_awesomeAnalysis

Sutro Biopharma, a clinical-stage oncology company, has finalized a significant public offering of 7,868,383 shares of common stock, raising approximately $102.7 million in net proceeds. This offering, priced at $13.98 per share (which was the last reported sale price on February 9, 2026), represents a substantial capital infusion for the company. The proceeds are earmarked for general corporate purposes, including funding critical research, clinical and process development, and manufacturing of its product candidates. This capital raise is projected to extend the company's cash runway into the second quarter of 2028, providing essential funding for its ongoing Phase 1 trial for STRO-004 and IND-enabling activities for other preclinical assets. While the offering is highly dilutive, increasing the outstanding share count by approximately 91.88% based on shares outstanding as of September 30, 2025, it secures vital capital for a biotech company at this stage of development, mitigating near-term liquidity concerns. The pricing at market on the day of the offering indicates a successful execution of the capital raise.